Skip to content


    DAE Class; Rx

    Common Brand Names; Orgovyx

    • Antineoplastics, GNRH Antagonists

    Gonadotropin-releasing hormone (GnRH) receptor antagonist; binds to and blocks GnRH receptors in the anterior pituitary gland

    Blocking GnRH receptors decreases the release of gonadotropins (ie, luteinizing hormone, follicle stimulating hormone), thereby decreasing the downstream production of testosterone by the testes in men

    Indicated for advanced prostate cancer


    All grades

    • Hot flush (54%)
    • Glucose increased (44%)
    • Triglycerides increased (35%)
    • Musculoskeletal pain (30%)
    • Hemoglobin decreased (28%)
    • ALT increased (27%)
    • Fatigue (26%)
    • AST increased (18%)
    • Diarrhea (12%)
    • Constipation (12%)


    All grades

    • Increased weight (<10%)
    • Insomnia (<10%)
    • Gynecomastia (<10%)
    • Hyperhidrosis (<10%)
    • Depression (<10%)
    • Decreased libido (<10%)

    Grade 3-4

    • Glucose increased (2.9%)
    • Triglycerides increased (2%)
    • Musculoskeletal pain (1.1%)


    Grade 3-4

    • Hot flush
    • Fatigue
    • Diarrhea
    • ALT increased
    • Hemoglobin increased

    Based animal studies and mechanism of action, fetal harm may occur

    Therapy suppresses pituitary gonadal system; results of diagnostic tests conducted during and after treatment may be affected; monitor therapeutic effect of relugolix by measuring serum concentrations of prostate specific antigen (PSA) periodically; if PSA increases, measure serum testosterone concentrations

    Hypersensitivity reactions, including pharyngeal edema and other serious cases of angioedema, reported; advise patients who experience any symptoms of hypersensitivity to temporarily discontinue therapy and promptly seek medical care; discontinue therapy for severe hypersensitivity reactions and manage as clinically indicated


    Based on findings in animals and mechanism of action, can cause fetal harm and loss of pregnancy when administered to pregnant females

    Human data are unavailable


    Data are unavailable on presence in human milk, effects on breastfed children, or effects on milk production

    Relugolix and/or its metabolites were present in milk of lactating rats at concentrations up to 10-fold higher than in plasma at 2 hr post dose

    Prostate Cancer

    Indicated for advanced prostate cancer

    Day 1 loading dose: 360 mg PO

    Maintenance dose: 120 mg PO qDay

    Dosing Considerations

    Correct electrolyte abnormalities

    Consider periodic ECG and electrolyte monitoring

    Males with female partners of reproductive potential should use effective contraception



    • 120mg